

K221987 Erchonia GVLSep 1, 2022
57 days to decisionK221987 · Product code: **NHN** · General & Plastic Surgery
Source: <https://www.510kdatabase.net/k221987/>**SUBMISSION DETAILS**

| | |
|-----------------------|---|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Traditional |
| Device classification | Powered Light Based Laser Non-thermal Instrument With Non-heating Effect For Adjunctive Use In Pain Therapy (NHN) |
| Date received | Jul 6, 2022 |
| Decision date | Sep 1, 2022 |
| Days to decision | 57 days |
| Third-party review | No |
| Combination product | No |
| PCCP authorized | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---|
| Company | Erchonia Corporation |
| Location | Fountain Inn, SC, US |
| Contact | Travis Sammons |
| Website | https://www.erchonia.com |
| 510(k) history | 26 submissions · 26 cleared · 2010-2026 |

Erchonia Corporation is a medical device manufacturer based in Fountain Inn, US, specializing in low-level laser technology for therapeutic applications. The company has received FDA 510(k) clearances from total submissions, with a regulatory track record spanning 2010 to 2026. Erchonia's cleared devices focus primarily on General & Plastic Surgery and Physical Medicine applications, including laser systems for pain management, fat loss, and tissue healing. The company remains actively engaged in FDA regulatory submissions, with its most recent clearance in 2026. Erchonia...

CLINICAL EVIDENCE - NCT00929305**Low Level Laser Light Therapy and Chronic Neck and Shoulder Pain**

| | |
|-------------------|--|
| Status | Completed |
| Enrollment | 100 patients (actual) |
| Condition studied | Shoulder Pain; Neck Pain; Musculoskeletal Pain; Musculoskeletal Strain; Musculoskeletal Sprain |
| Primary purpose | Treatment |
| Study type | Interventional |
| Study design | Parallel |
| Masking | Triple |
| Completion date | Jun 1, 2001 |
| Sponsor | Erchonia Corporation (Industry) |

Primary outcome

The Number of Participants Whose Self-reported Pain Rating in the Neck and Shoulder Area on the 0-100 Visual Analog Scale (VAS) Decreased by 30% or More From Baseline to One Day After Study Treatment

Secondary outcome

Range of Motion of the Neck and Shoulders

Source: ClinicalTrials.gov / U.S. National Library of Medicine - clinicaltrials.gov/study/NCT00929305

